Biosimilars, Compounding and Mayo Clinic

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacy Times

JUNE 24, 2025

In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at Mayo Clinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.

Pharmacy Technician

Pharmacy Technician Diabetes Inpatient Compounding Pharmacies

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

JUNE 16, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Accessed June 16, 2025. Ferruggia K. Pharmacy Times.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Dosage Hospitals

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Immunity Immunization

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacy Times

JULY 7, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma. News release.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. This governance issue is a very hot topic,” Eric M.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Pharmacy Management Hospitals

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

JULY 9, 2025

Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A. Pharmacy Times.

Labelling

Labelling Pharmacy Technician Independent Pharmacies Compounding Pharmacies

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

Pharmacy Times

JUNE 26, 2025

In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Vaccines Pharmacy Management

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

Pharmacy Times

JUNE 24, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. McGovern G. Prevalence of CKD in Patients With LN and SLE Ranges From 10% to Almost 50%, Review Finds. Pharmacy Times. February 4, 2025.

Pharmacy Technician

Pharmacy Technician Diabetes Compounding Pharmacies Vaccines

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

Pharmacy Times

JUNE 9, 2025

Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunity

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

The treatment works by combining a targeting compound with a therapeutic radioisotope. Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. News release. July 9, 2025. Accessed July 10, 2025. News release.

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from Mayo Clinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.

Chemotherapy

Chemotherapy Pharmacy Technician Compounding Pharmacies Hospitals

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Pharmacy Times

JUNE 15, 2025

Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to Mayo Clinic. Mayo Clinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.

Pharmacy Technician

Pharmacy Technician Mayo Clinic Compounding Pharmacies Pharmacy Management

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

Pharmacy Times

JULY 18, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults. EuerkAlert!

Pharmacy Technician

Pharmacy Technician Compounding Pharmacies Compounding Diabetes

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Pharmacy Times

JULY 14, 2025

Mayo Clinic. " 1 REFERENCES 1. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation. Accessed July 7, 2025. Boston Scientific. FARAPULSE™ Pulsed Field Ablation System. Accessed July 7, 2025.

Labelling

Labelling Pharmacy Technician Compounding Pharmacies Hospitals

Pharmacist Digest

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Trending Sources

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacists Take the Lead on Advanced Therapeutics

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Stay Connected